Jump to any asset
850 assets, updated daily
As of September 11, 2026, Hims & Hers Health, Inc. (HIMS) trades at $27.52. CleaRank Financial AI rates it Hold with a fair value of $27.52, in line with the current price. Wall Street's consensus target is $31.00 across 15 analysts. RSI at 28 is in oversold territory, and the price is below its 50-day average of $31.04.
Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. NYSE
$27.52
0.0750 (0.27%)
At close: Sep 11, 4:00 PM EDT
AI Analyst Consensus
58 / 100
Hims & Hers Health, Inc. (HIMS) is currently trading at $27.515, below its 50-day and 200-day moving averages ($31.04 and $28.23), signaling a bearish technical trend. The company has demonstrated strong revenue growth of 38.2% year-over-year, with Wall Street revenue estimates projecting further acceleration to 49.00% for the current quarter and 54.00% for the next. However, a significant insider sell-off, with $404.5M in total sales versus $7.2M in total purchases, casts a shadow over the company's prospects. The consensus rating among 15 Wall Street analysts is 'Hold', with a median price target of $31, implying a modest 12.7% upside potential.
HIMS Price Analysis
Market Metrics
Open
$27.20
Day Range
$26.74 to $27.62
Prev Close
$27.44
Volume
237.8K
52-Week Range
$13.74 to $65.30
Market Cap
$6.40B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a significant premium to sector peers (+124%), suggesting market expectations for superior growth or market position.
HIMS Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 3 quarters, HIMS beat estimates 2 times. However, the stock fell 2 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
HIMS Analysis
Company's Health
2/5
12-Month Analyst Target
+12.67% Upside
Median of 15 analysts (12-month)
$31.00
AI Technical Analysis
Hims & Hers Health, Inc. (HIMS) is exhibiting bearish momentum, trading below its 50-day SMA of $31.04 and its 200-day SMA of $28.23. The Relative Strength Index (RSI) is at 28.09, indicating oversold conditions, which could suggest a potential for a short-term bounce. However, the MACD is negative at -0.845, reinforcing the prevailing downward trend. Volume has been significantly below average, with the latest volume at 237,756 compared to an average of 8,242,736, suggesting a lack of conviction behind current price action.
ProTips
- Given the heavy insider selling signal from HIMS, consider reducing exposure or waiting for a clearer bullish catalyst before initiating new positions.
- The oversold RSI reading of 28.09 suggests a potential for a short-term bounce, but this should be viewed with caution given the prevailing bearish trend and insider selling.
- With a negative EPS and recent earnings misses, it is advisable to scrutinize the company's path to profitability and its ability to sustain revenue growth.
Key Catalysts
Bearish
Heavy Insider Selling Pressure
Insiders have sold $170.5 million worth of HIMS stock versus only $1.2 million in purchases, indicating a strong bearish sentiment from management.
Source: Insider Trading DataBearish
Trading Below Key Moving Averages
HIMS is trading below its 50-day SMA ($31.04) and 200-day SMA ($28.23), signaling a bearish technical trend and potential for further price declines.
Source: Technical AnalysisBearish
Recent Earnings Misses
The company missed EPS estimates significantly in its latest two earnings reports, leading to notable stock price declines.
Source: Earnings ReportsBullish
Strong Revenue Growth Projections
Wall Street revenue estimates show strong year-over-year growth, with the current quarter projected at +49.00% and the next quarter at +54.00%.
Source: Wall Street EstimatesMarket Outlook
The outlook for Hims & Hers Health, Inc. (HIMS) is cautiously bearish in the near term, given the heavy insider selling and negative technical indicators. While the company continues to exhibit impressive revenue growth, outpacing sector averages, the persistent earnings misses and the significant disposition of shares by insiders suggest potential headwinds. The median Wall Street price target of $31 indicates limited upside, and the stock's position below key moving averages reinforces a bearish bias. Investors should monitor upcoming earnings reports and insider activity closely for any shifts in sentiment.
Key Statistics
| Market Cap | 6.40B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -0.6300 |
| Dividend Yield | 0.00% |
| 52 Week High | 65.30 |
| 52 Week Low | 13.74 |
Hims & Hers Health, Inc. (HIMS) exhibits a negative EPS of -0.63, making its P/E ratio mathematically negative and thus not a useful valuation metric. The company's revenue growth of 38.2% is strong, outpacing the sector average of 10.0%, and forward estimates show continued strong growth. Despite this top-line expansion, the significant insider selling totaling $170.5 million raises concerns about management's confidence in the current valuation. The median Wall Street price target of $31 suggests a limited upside from the current price, indicating that the market may be pricing in these concerns.
Earnings & Growth Analysis
Hims & Hers Health, Inc. (HIMS) most recently reported an EPS of -0.37 for the quarter ending August 10, 2026, missing the estimate of -0.05 by a significant 640% and leading to a 3.97% price drop. Prior to this, the company missed estimates in the May 11, 2026 quarter by 246.15%, resulting in a 14.1% stock decline. While there was a positive EPS surprise in February 2026, the recent trend indicates a pattern of earnings misses that could weigh on future performance.
Key Risks
The primary risk for Hims & Hers Health, Inc. (HIMS) is the heavy insider selling signal, with over $170 million in sales by insiders, suggesting a lack of confidence in the current stock price. Additionally, the stock is trading below key moving averages (50-day and 200-day SMA), indicating a bearish technical trend and potential for further downside. The company's negative EPS and recent earnings misses also present a fundamental risk, despite strong revenue growth.
Technical Indicators
| RSI (14) | 28.09 |
|---|---|
| MACD | -0.85 |
| SMA 50 | 31.04 |
| SMA 200 | 28.23 |
RSI
Oversold
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($31.04) above the 200-day SMA ($28.23), price is trading below the 50-day SMA, RSI at 28.1 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.37
Weak correlation
Nasdaq 100 (QQQ)
+0.39
Weak correlation
Bitcoin (BTC)
+0.36
Weak correlation
Gold (XAU)
+0.09
Weak correlation
Check Custom Correlation
Calculating correlation...
HIMS Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies (click to switch)
CONSERVATIVE
$27.24
Slight discount to current
Wait for small dip
AGGRESSIVE
$27.52
At current price
Enter now if confident
Risk Management
STOP LOSS
$24.92
MAX LOSS
-8.5%
Volatility-Adjusted Stop Loss
Calculated based on RSI (28.1) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$28.06
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$28.60
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$29.42
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
HIMS is classified as a high-volatility asset (Daily Vol: 5.15%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in HIMS in September 2019 would be worth about $28,000 today, compared with about $25,170 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in HIMS today could grow to about $29,073 by 2036 in the base case, with a bull case near $220,568 and a bear case around $3,832. Projections are statistical simulations, not guarantees.
HIMS Stock Price Prediction: 2030
CleaRank's simulation projects a price near $42.17 for HIMS by 2030 in the base case, from $27.52 today (1.5x over 4 years). The downside path ends near $11.71. These are outcomes of a Monte Carlo simulation run on HIMS's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $16.13 | $30.61 | $58.11 |
| 2028 | $13.76 | $34.06 | $84.30 |
| 2029 | $12.49 | $37.90 | $115 |
| 2030 | $11.71 | $42.17 | $152 |
| 2031 | $11.20 | $46.92 | $197 |
| 2032 | $10.86 | $52.20 | $251 |
| 2033 | $10.66 | $58.08 | $316 |
| 2034 | $10.55 | $64.62 | $396 |
| 2035 | $10.52 | $71.90 | $492 |
| 2036 | $10.54 | $79.99 | $607 |
Method: 10,000 simulated price paths using HIMS's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. HIMS is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
HIMS Insider Trading Analysis
Bought
$1.2M
1 Transactions
Sold
$170.5M
99 Transactions
Insiders
17
Active Traders
Avg Transaction
$1.7M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 7, 2025 | DUDUM ANDREW
Chief Executive Officer
|
Sell | 660.0K | $33.4M |
| Mar 2, 2023 | BARD ALEX
Director
|
Sell | 2.8M | $30.8M |
| Jun 17, 2025 | DUDUM ANDREW
Chief Executive Officer
|
Sell | 240.8K | $13.8M |
| Oct 16, 2025 | DUDUM ANDREW
Chief Executive Officer
|
Sell | 175.7K | $11.0M |
| Jun 3, 2024 | CHI MICHAEL
Officer
|
Sell | 521.4K | $10.3M |
| May 16, 2025 | DUDUM ANDREW
Chief Executive Officer
|
Sell | 175.7K | $10.3M |
| Feb 18, 2025 | DUDUM ANDREW
Chief Executive Officer
|
Sell | 175.7K | $10.2M |
| Sep 16, 2025 | DUDUM ANDREW
Chief Executive Officer
|
Sell | 175.7K | $9.4M |
| Jun 11, 2024 | CHI MICHAEL
Officer
|
Sell | 392.2K | $8.6M |
| Mar 18, 2025 | DUDUM ANDREW
Chief Executive Officer
|
Sell | 254.4K | $8.6M |
Page 1 of 1
Frequently Asked Questions
What is Hims & Hers Health, Inc.'s current stock price and consensus rating?
As of September 11, 2026, Hims & Hers Health, Inc. (HIMS) is trading at $27.515. The consensus rating among 15 Wall Street analysts is 'Hold'.
What is the median analyst price target for HIMS stock?
The median analyst price target for Hims & Hers Health, Inc. (HIMS) is $31.00, implying an upside of 12.7% from the current price.
What is the recent insider trading activity for HIMS?
Insiders of Hims & Hers Health, Inc. (HIMS) have been net sellers, with total sales amounting to $170.5 million compared to $1.2 million in purchases, indicating a heavy sell signal.
How is HIMS performing technically?
Hims & Hers Health, Inc. (HIMS) is currently trading below its 50-day and 200-day moving averages ($31.04 and $28.23), with an RSI at 28.1 suggesting oversold conditions, but the MACD indicates bearish momentum.
What are the revenue growth prospects for HIMS?
Hims & Hers Health, Inc. (HIMS) has demonstrated strong year-over-year revenue growth of 38.2%, with Wall Street projecting continued acceleration to 49.00% for the current quarter and 54.00% for the next.
What are the main risks facing Hims & Hers Health, Inc.?
Key risks include significant insider selling pressure, a bearish technical trend indicated by price action below moving averages, and recent earnings misses despite strong revenue growth.
What is HIMS stock forecast for 2030?
Based on Monte Carlo simulations, Hims & Hers Health, Inc.'s (HIMS) stock forecast for 2030 shows a base case price of $42.17, with a downside projection of $11.71 and an upside projection of $151.9. These are statistical outcomes, not price targets.